IRulya Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut. The company adopted the IRulya name in October 2026, following its transformation from Quince Therapeutics, Inc., which had previously operated under the name Cortexyme. Its business is focused on developing treatments for serious pulmonary diseases that have limited treatment options, with an emphasis on therapies designed to address the underlying biological processes responsible for disease progression. Its common stock trades on the Nasdaq Capital Market under the ticker IRLA.
The company's lead drug candidate, LAM-001, is an investigational, once-daily inhaled formulation of rapamycin, a drug that inhibits a cellular signaling pathway known as mTOR. This pathway plays a role in cell growth, inflammation and tissue repair, and its abnormal activity is implicated in several pulmonary diseases. By delivering rapamycin directly to the lungs through a dry-powder inhaler, IRulya aims to achieve therapeutic effects at the site of disease while limiting exposure elsewhere in the body. LAM-001 remains under clinical investigation and has not been established as an approved treatment for these conditions.
IRulya is evaluating LAM-001 across three principal indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome following lung transplantation (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). These conditions can cause progressive damage to lung tissue, scarring, restricted airflow or increased pressure in the blood vessels supplying the lungs. The company has completed an early Phase 2a study involving pulmonary hypertension patients and is conducting further Phase 2 studies in PH-ILD and BOS, with a study in SAPH planned for late 2026. Its future development will depend on clinical trial results, regulatory review and its ability to advance the treatment toward potential approval.